Compare · IQV vs OABI
IQV vs OABI
Side-by-side comparison of IQVIA Holdings Inc. (IQV) and OmniAb Inc. (OABI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IQV and OABI operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- IQV is the larger of the two at $30.66B, about 92.8x OABI ($330.5M).
- IQV has hit the wire 5 times in the past 4 weeks while OABI has been quiet.
- IQV has more recent analyst coverage (25 ratings vs 5 for OABI).
- Company
- IQVIA Holdings Inc.
- OmniAb Inc.
- Price
- $183.69+0.14%
- $2.27-8.28%
- Market cap
- $30.66B
- $330.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NYSE
- NASDAQ
- IPO
- 2013
- 2021
- News (4w)
- 5
- 0
- Recent ratings
- 25
- 5
IQVIA Holdings Inc.
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Latest IQV
- SEC Form 8-K filed by IQVIA Holdings Inc.
- IQVIA Announces Pricing of Senior Notes
- SEC Form 8-K filed by IQVIA Holdings Inc.
- IQVIA Announces Offering of Senior Notes
- IQVIA CEO to Speak at Jefferies Global Healthcare Conference
- IQVIA and Kexing Biopharm Expand Strategic Collaboration to Accelerate Global Biosimilar Development using AI-Enabled Capabilities
- SEC Form 4 filed by Director Wims Morris Leslie
- SEC Form 4 filed by Director Goggins Colleen A
- SEC Form 4 filed by Director Fasano Jim
- SEC Form 4 filed by Director Danhakl John G
Latest OABI
- SEC Form 10-Q filed by OmniAb Inc.
- OmniAb Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- OmniAb Reports First Quarter 2026 Financial Results and Business Highlights
- SEC Form DEF 14A filed by OmniAb Inc.
- SEC Form DEFA14A filed by OmniAb Inc.
- OmniAb to Participate in Three Upcoming Investor Conferences
- SEC Form 4 filed by Gotwals Philip J
- SEC Form 4 filed by Crouse Steven C.
- OmniAb to Report First Quarter 2026 Financial Results on May 7
- SEC Form 144 filed by OmniAb Inc.